POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

ASCO 2025: Importance of early testing in metastatic prostate cancer

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer

Disparities in mammogram screening amongst LGBTQ+ populations

New MOAs in prostate cancer treatment - what’s next?

Barriers to global oncology clinical trial participation in sub-Saharan Africa

Social determinants and survival outcomes in early-onset colorectal cancer in the US

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics

ASCO 2025: Update on blood-based cancer assays